Design Therapeutics Stock Working Capital
| DSGN Stock | USD 3.52 0.20 5.38% |
Design Therapeutics fundamentals help investors to digest information that contributes to Design Therapeutics' financial success or failures. It also enables traders to predict the movement of Design Stock. The fundamental analysis module provides a way to measure Design Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Design Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 275 M | 222.1 M | |
| Change In Working Capital | -1.2 M | -1.2 M | |
| Working Capital | 0.00 | 0.00 |
Design | Working Capital |
Design Therapeutics Company Working Capital Analysis
Design Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Design Therapeutics Working Capital | 274.96 M |
Most of Design Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Design Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Design Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Design Therapeutics is extremely important. It helps to project a fair market value of Design Stock properly, considering its historical fundamentals such as Working Capital. Since Design Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Design Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Design Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Design Net Invested Capital
Net Invested Capital |
|
According to the company's disclosures, Design Therapeutics has a Working Capital of 274.96 M. This is 35.4% lower than that of the Biotechnology sector and 48.95% lower than that of the Health Care industry. The working capital for all United States stocks is 81.4% higher than that of the company.
Design Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Design Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Design Therapeutics could also be used in its relative valuation, which is a method of valuing Design Therapeutics by comparing valuation metrics of similar companies.Design Therapeutics is currently under evaluation in working capital category among related companies.
Design Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (68.59 M) | ||||
| Shares Outstanding | 56.49 M | ||||
| Shares Owned By Insiders | 36.66 % | ||||
| Shares Owned By Institutions | 56.74 % | ||||
| Number Of Shares Shorted | 2.39 M | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 22,642 X | ||||
| Gross Profit | (48.61 M) | ||||
| EBITDA | (78.19 M) | ||||
| Net Income | (66.86 M) | ||||
| Cash And Equivalents | 359.38 M | ||||
| Cash Per Share | 6.45 X | ||||
| Total Debt | 2.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 48.96 X | ||||
| Book Value Per Share | 4.92 X | ||||
| Cash Flow From Operations | (58.56 M) | ||||
| Short Ratio | 6.07 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Target Price | 4.67 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.83 | ||||
| Market Capitalization | 210.16 M | ||||
| Total Asset | 289.64 M | ||||
| Retained Earnings | (177.63 M) | ||||
| Working Capital | 274.96 M | ||||
| Net Asset | 289.64 M |
About Design Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Design Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Design Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Design Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Design Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Design Stock
| 0.85 | ETON | Eton Pharmaceuticals Financial Report 9th of May 2024 | PairCorr |
| 0.77 | EVOK | Evoke Pharma | PairCorr |
| 0.67 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.66 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.5 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Design Therapeutics Piotroski F Score and Design Therapeutics Altman Z Score analysis. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.Note that the Design Therapeutics information on this page should be used as a complementary analysis to other Design Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Design Stock analysis
When running Design Therapeutics' price analysis, check to measure Design Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Design Therapeutics is operating at the current time. Most of Design Therapeutics' value examination focuses on studying past and present price action to predict the probability of Design Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Design Therapeutics' price. Additionally, you may evaluate how the addition of Design Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Design Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Revenue Per Share 0.001 | Return On Assets (0.15) | Return On Equity (0.22) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.